FGF2 and ulcer disease: Subsequently, AFG was administered to 50% of the area of each ulcer and observed for 4 weeks in comparison with recombinant basic fibroblast growth factor with bucladesine sodium treatment that was administered to the rest of the ulcer.<h4>Outcomes</h4>The skin ulcer after trauma in participant 1 showed better improvement in the AFG-treated area.